Tải bản đầy đủ (.pdf) (3 trang)

Andersons pediatric cardiology 1671

Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.49 KB, 3 trang )

andclinicalfeaturesofcostellosyndromeand
cardio-facio-cutaneoussyndromeinJapan:
findingsfromanationwideepidemiological
survey.AmJMedGenetA.2012;158A(5):1083–
1094.
120.AllansonJE,AnnerenG,AokiY,etal.Cardiofacio-cutaneoussyndrome:doesgenotype
predictphenotype?AmJMedGenetCSemin
MedGenet.2011;157C(2):129–135.
121.NishinoI,FuJ,TanjiK,etal.PrimaryLAMP-2
deficiencycausesX-linkedvacuolar
cardiomyopathyandmyopathy(danondisease).
Nature.2000;406(6798):906–910.
122.NgKM,MokPY,ButlerAW,etal.Amelioration
ofX-linkedrelatedautophagyfailureindanon
diseasewithDNAmethylationinhibitor.
Circulation.2016;134(18):1373–1389.
123.YangZ,McMahonCJ,SmithLR,etal.Danon
diseaseasanunderrecognizedcauseof
hypertrophiccardiomyopathyinchildren.
Circulation.2005;112(11):1612–1617.
124.AradM,MaronBJ,GorhamJM,etal.Glycogen
storagediseasespresentingashypertrophic
cardiomyopathy.NEnglJMed.
2005;352(4):362–372.
125.MaronBJ,RobertsWC,AradM,etal.Clinical
outcomeandphenotypicexpressioninLAMP2


cardiomyopathy.JAMA.2009;301(12):1253–
1259.
126.CharronP,VillardE,SebillonP,etal.Danon's


diseaseasacauseofhypertrophic
cardiomyopathy:asystematicsurvey.Heart.
2004;90(8):842–846.
127.BoucekD,JirikowicJ,TaylorM.Naturalhistory
ofdanondisease.GenetMed.2011;13(6):563–
568.
128.ChengZ,CuiQ,TianZ,etal.Danondiseaseas
acauseofconcentricleftventricular
hypertrophyinpatientswhounderwent
endomyocardialbiopsy.EurHeartJ.
2012;33(5):649–656.
129.SugieK,YamamotoA,MurayamaK,etal.
Clinicopathologicalfeaturesofgenetically
confirmeddanondisease.Neurology.
2002;58(12):1773–1778.
130.StokesMB,TaylorAJ,McLeanCA,D'ArcyCE,
MarianiJA.Severeleftventricularhypertrophy
andmarkedcardiacfibrosisindanondisease.Int
JCardiol.2016;221:14–16.
131.MianiD,TaylorM,MestroniL,etal.Sudden
deathassociatedwithdanondiseaseinwomen.
AmJCardiol.2012;109(3):406–411.
132.FinstererJ,StollbergerC,MaeztuC.Sudden
cardiacdeathinneuromusculardisorders.IntJ


Cardiol.2016;203:508–515.
133.ThevenonJ,LaurentG,AderF,etal.High
prevalenceofarrhythmicandmyocardial
complicationsinpatientswithcardiac

glycogenosisduetoPRKAG2mutations.
Europace.2016.
134.GollobMH,SegerJJ,GollobTN,etal.Novel
PRKAG2mutationresponsibleforthegenetic
syndromeofventricularpreexcitationand
conductionsystemdiseasewithchildhoodonset
andabsenceofcardiachypertrophy.Circulation.
2001;104(25):3030–3033.
135.MurphyRT,MogensenJ,McGarryK,etal.
Adenosinemonophosphate-activatedprotein
kinasediseasemimickshypertrophic
cardiomyopathyandWolff-parkinson-white
syndrome:naturalhistory.JAmCollCardiol.
2005;45(6):922–930.
136.LuptakI,ShenM,HeH,etal.Aberrant
activationofAMP-activatedproteinkinase
remodelsmetabolicnetworkinfavorofcardiac
glycogenstorage.JClinInvest.
2007;117(5):1432–1439.
137.AradM,MoskowitzIP,PatelVV,etal.
Transgenicmiceoverexpressingmutant
PRKAG2definethecauseofWolff-parkinsonwhitesyndromeinglycogenstorage



×